메뉴 건너뛰기

Plenary Lecture

Home > 프로그램 > Plenary Lecture
John R. Yates III
Date
25 June
Speaker
John R. Yates III   CV
Affiliation
Scripps Research Institute
Title
Understanding the disease Cystic Fibrosis through Protein Interactions, Modifications, and Structure

 

Woong-Yang Park
Date
25 June
Speaker
Woong-Yang Park   CV
Affiliation
Samsung Medical Center
Title
TBA

 

Naoyuki Taniguchi
Date
26 June
Speaker
Naoyuki Taniguchi   CV
Affiliation
Osaka international Cancer Institute
Title
Glyco-redox and its Role in EMT/MET and Cancer  
Abstract

Glycans are biosynthesized by a specific glycosyltransferase and each glycosyltransferase is either directly or indirectly regulated via transcriptional factors, epigenetic modification, chaperon, availability of donor and acceptor substrates including sugar nucleotides, and competitive enzyme activity under oxidative stress. Therefore, glycomics is also one of the important research fields in human proteome. We proposed previously the concept of Glyco-redox which explains the interaction of reduction/oxidation (redox) and glycosylation (1) and involved in the endothelial mesenchymal transition (EMT) and mesenchymal epithelial transition (MET) processes that are highly associated with the onset of various diseases such as cancer and fibrosis (2).
The present studies introduce a typical example of Glyco-redox. One of the antioxidative enzyme SOD3 (extracellular SOD) has N-glycans with sialic acid and core fucose glycans that play important roles in secretion and in the ability to suppress the growth of cancer cell lines.
Recently several papers have described deep insight to describe the concept of Glyco-redox. This mini review describes the significance of Glyco-redox in EMT/MET and the roles of major N-glycan glycosyltransferases GnT-III, GnT-V, ST6Gal1, and Fut8. Herein, we also identify their target proteins and discuss the significance of their products. A clear-cut understanding of the significance of Glyco-redox in relation to the EMT/MET process is essential to develop biomarker discovery and treatments for these diseases.

References
1)Taniguchi N. et al. Arch Biochem Biophys. 2016 Apr 1;595:72-80.
2)Taniguchi N, Kizuka Y. Adv Cancer Res. 2015;126:11-51.

 

Charles Pineau
Date
27 June
Speaker
Charles Pineau
Affiliation
French Institute of Health and Medical Research (Inserm)
Title
TBA

 

Youngsoo KIM
Date
27 June
Speaker
Youngsoo KIM   CV
Affiliation
CHA University
Title
A Road to Develop MRM-MS as a Diagnostic Platform: Surveillance Diagnosis for Hepatocellular Carcinoma (HCC)
Abstract

Conventional methods for hepatocellular carcinoma (HCC) surveillance, including imaging and serum tumor markers (AFP and PIVKA-II), have limited accuracy. To improve diagnostic performance, we explored three approaches using mass spectrometry techniques.
Firstly, we aimed to develop an analytically sensitive multiple reaction monitoring-mass spectrometry (MRM-MS) assay to quantify AFP-L3 in serum. The performance of the MRM-MS assay was compared with that of LiBA (liquid-phase binding assay using capillary electrophoresis) in human serum samples. Integrated multinational guidelines were followed to validate the assay for clinical implementation. Secondly, we aimed to develop assays for protein induced by vitamin K absence or antagonist-II (PIVKA-II, DCP) using MRM-MS instead of antibody assays. We tried to improve the DCP measurement assay by applying a mass-spectrometry (MS)-based approach for a more inclusive quantification of various DCP proteoforms. We developed a multiple reaction monitoring-MS (MRM-MS) assay to quantify multiple non-carboxylated peptides included in the various des-carboxylation states of DCP. The quantitative DCP assay using the MRM-MS method is superior to antibody-based quantification, with equivalent performance. Thirdly, we aimed to develop a serum multi-protein marker panel using MRM-MS, aiming to improve diagnostic accuracy. We have developed and validated a reliable serum biomarker panel for the early detection of HCC. Finally, we developed a multiple reaction monitoring-mass spectrometry (MRM-MS) multi-marker panel using marker proteins from the sera of patients.
Collectively, these three approaches would have the potential to enhance Surveillance Diagnosis for Hepatocellular Carcinoma (HCC).